Today, a settlement agreement was announced in the Pradaxa mass torts MDL litigation. Terms of the agreement are not readily available but initial reports have the settlement at $650 million. There are approximately 4,000 claimants in the MDL.
Pradaxa is a blood thinner marketed to compete with warfarin, or coumadin. Side effects claimed in the lawsuits are bleeding events and death.
